Skip to main content
SpringerLink
Log in

Pharmacologic treatment of impulsive aggression with antiepileptic drugs

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Aggressive behavior is a major concern in mental health and criminal justice settings. Although pharmacotherapy is often used in the treatment of the violent individual, no medication is presently approved by the US Food and Drug Administration specifically for such use. In recent years, antiepileptic drugs (AEDs) have become increasingly popular for the management of impulsive (reactive) aggressive behavior. The research literature has implicated several neurobiologic deficits associated with impulsive aggression, including reduced central serotonergic functioning, executive dysfunction, and prefrontal deficits. It has been suggested that the neurobiologic deficits specific to impulsive aggressive behavior may serve as indicators of an ineffective behavioral control system. A review of the literature finds that AEDs, particularly those that block sodium channels and/or have GABA-related mechanisms of action, are effective in reducing the frequency and intensity of impulsive aggressive outbursts both when used as the primary agent of treatment and as an adjunct to ongoing pharmacotherapy. Strong evidence for efficacy in impulsive aggression exists from randomized controlled trials for most of the common AEDs (phenytoin, carbamazepine, oxcarbazepine, lamotrigine, valproate/divalproex sodium, topiramate). Additional controlled studies are needed for tiagabine and gabapentin. Of the common AEDs, only levetiracetam has been shown to be ineffective in the treatment of impulsive aggression. It is important to note that the anti-aggressive effects seen with the AEDs appear to be specific to the impulsive form of aggression. Individuals who display premeditated aggression do not seem to benefit from this type of treatment. Clinically, we recommend phenytoin (initial dose 100 mg three times daily) as the AED of first choice for the treatment of impulsive aggressive outbursts. This recommendation is based on this drug’s limited side effect profile (compared with the other AEDs) and the large amount of empiric data supporting its clinical efficacy in impulsive aggression. In the event that the impulsive aggressive individual does not respond to pharmacotherapy with phenytoin, carbamazepine (initial dose 150 mg three times daily) and valproate/divalproex sodium (initial dose 250 mg three times daily) have both proved to be effective secondary options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Houston RJ, Stanford MS, Villemarette-Pittman NR, et al.: Neurobiological correlates and clinical implications of aggressive subtypes. J Forensic Neuropsychol 2003, 3:67–87.

    Article  Google Scholar 

  2. Barratt ES: Measuring and predicting aggression within the context of a personality theory. J Neuropsychiatry Clin Neurosci 1991, 3:s35–s39.

    PubMed  CAS  Google Scholar 

  3. Raine A, Meloy JR, Bihrle S, et al.: Reduced prefrontal and increased subcortical brain functioning assessed using positron emission tomography in predatory and affective murderers. Behav Sci Law 1998, 16:319–332.

    Article  PubMed  CAS  Google Scholar 

  4. Dodge KA, Coie JD: Social-information-processing factors in reactive and proactive aggression in children’s peer groups. J Pers Soc Psychol 1998, 53:1146–1158.

    Google Scholar 

  5. Barratt ES, Stanford MS, Felthous AR, Kent TA: The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 1997, 17:341–349.

    Article  PubMed  CAS  Google Scholar 

  6. Houston RJ, Stanford MS: Mid-latency evoked potential in self-reported impulsive aggression. Int J Psychophysiol 2001, 40:1–15.

    Article  PubMed  CAS  Google Scholar 

  7. Stanford MS, Houston RJ, Villemarette-Pittman NR, Greve KW: Premeditated aggression: clinical assessment and cognitive psychophysiology. Pers Individ Dif 2003, 34:773–781.

    Article  Google Scholar 

  8. Keele NB: The role of serotonin in impulsive and aggressive behaviors associated with epilepsy-like neuronal hyperexcitability in the amygdala. Epilepsy Behav 2005, 7:325–335.

    Article  PubMed  Google Scholar 

  9. Peterson J, Sheldon C: Treating persistent adolescent aggression. Curr Treat Options Neurol 2006, 8:427–438.

    Article  PubMed  Google Scholar 

  10. Stanford MS, Helfritz LE, Conklin SM, et al.: A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol 2005, 13:72–77.

    Article  PubMed  CAS  Google Scholar 

  11. Motohashi N: GABA receptor alterations after chronic lithium administration: comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 1992, 16:571–579.

    Article  PubMed  CAS  Google Scholar 

  12. Tunnicliff G: Basis of the antiseizure action of phenytoin. Gen Pharmacol 1996, 27:1091–1097.

    PubMed  CAS  Google Scholar 

  13. Zheng T, Clarke AL, Morris MJ, et al.: Oxcarbazepine, not its active metabolite, potentiates GABA(A) activation and aggravates absence seizures. Epilepsia 2008, 50:83–87.

    Article  PubMed  CAS  Google Scholar 

  14. Li X, Ketter TA, Frye MA: Synaptic, intracellular and neuroprotective mechanisms of anticonvulsants: Are they relevant for the treatment and course of bipolar disorders? J Affect Disord 2002, 69:1–14.

    Article  PubMed  CAS  Google Scholar 

  15. Wasserman S, Iyengar R, Chaplin WF, et al.: Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006, 21:363–367.

    Article  PubMed  Google Scholar 

  16. Mattes JA: Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychiatry 2008, 69:310–315.

    Article  PubMed  CAS  Google Scholar 

  17. Cueva JE, Overall JE, Small AM, et al.: Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996, 35:480–490.

    Article  PubMed  CAS  Google Scholar 

  18. MacMillan CM, Korndörfer SR, Rao S, et al.: A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. J Psychiatr Pract 2006, 12:214–222.

    Article  PubMed  Google Scholar 

  19. Hellings JA, Weckbaugh RN, Nickel MS, et al.: A doubleblind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005, 15:682–692.

    Article  PubMed  Google Scholar 

  20. Stanford MS, Houston RJ, Mathias CW, et al.: A doubleblind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. Psychiatry Res 2001, 103:193–203.

    Article  PubMed  CAS  Google Scholar 

  21. Gardner DL, Cowdry RW: Positive effects of carbamazepine on behavioral discontrol in borderline personality disorder. Am J Psychiatry 1986, 143:519–522.

    PubMed  CAS  Google Scholar 

  22. Foster HG, Hillbrand M, Chi CC: Efficacy of carbamazepine in assaultive patients with frontal lobe dysfunction. Prog Neuropsychopharmacol Biol Psychiatry 1989, 13:865–874.

    Article  PubMed  CAS  Google Scholar 

  23. Nagata T, Harada D, Aoki K, et al.: Effectiveness of carbamazepine for benzodiazepine-resistant impulsive aggression in a patient with frontal lobe infarctions. Psychiatry Clin Neurosci 2007, 61:695–697.

    Article  PubMed  CAS  Google Scholar 

  24. Mattes JA: Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2005, 25:575–579.

    Article  PubMed  CAS  Google Scholar 

  25. Vieta E, Cruz N, García-Campayo J, et al.: A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008, 11:445–452.

    Article  PubMed  CAS  Google Scholar 

  26. Tritt K, Nickel C, Lahmann C, et al.: Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005, 19:287–291.

    Article  PubMed  CAS  Google Scholar 

  27. Lieberich P, Nickel MK, Tritt K, et al.: Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up. J Psychopharmacol 2008, 22:805–808.

    Article  Google Scholar 

  28. Pavlovic ZM: Lamotrigine for the treatment of impulsive aggression and affective symptoms in a patient with borderline personality disorder comorbid with body dysmorphic disorder. J Neuropsychiatry Clin Neurosci 2008, 20:121–122.

    PubMed  Google Scholar 

  29. Lieving LM, Cherek DR, Lane SD, et al.: Effects of acute tiagabine administration on aggressive responses of adult male parolees. J Psychopharmacol 2008, 22:144–152.

    Article  PubMed  CAS  Google Scholar 

  30. Hoffman DA: Tiagabine for rage, aggression and anxiety. J Neuropsychiatry Clin Neurosci 2005, 17:252.

    PubMed  Google Scholar 

  31. Kaufman KR, Kugler SL, Sachdeo RC: Tiagabine in the management of postencephalitic epilepsy and impulse control disorder. Epilepsy Behav 2002, 3:190–194.

    Article  PubMed  Google Scholar 

  32. Cherek DR, Tcheremissine OV, Lane SD, Pietras CJ: Acute effects of gabapentin on laboratory measures of aggressive and escape responses of adult parolees with and without a history of conduct disorder. Psychopharmacology 2004, 171:405–412.

    Article  PubMed  CAS  Google Scholar 

  33. Moretti R, Torre P, Antonello RM, Cazzato G: Gabapentin as a possible treatment of behavioral alterations in Alzheimer disease (AD) patients. Eur J Neurol 2001, 8:501–502.

    Article  PubMed  CAS  Google Scholar 

  34. Biancosine B, Facchi A, Marmai L, Grassi L: Gabapentin treatment of impulsive-aggressive behaviour. Can J Psychiatry 2002, 47:483–484.

    Google Scholar 

  35. Donovan SJ, Stewart JW, Nunes EV, et al.: Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000, 157:818–820.

    Article  PubMed  CAS  Google Scholar 

  36. Hollander E, Tracy K, Swann A, et al.: Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003, 28:1186–1197.

    Article  PubMed  CAS  Google Scholar 

  37. Nickel MK, Nickel C, Kaplan P, et al.: Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005, 57:495–499.

    Article  PubMed  CAS  Google Scholar 

  38. Nickel MK, Loew TH: Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. Eur Psychiatry 2008, 23:115–117.

    Article  PubMed  Google Scholar 

  39. Nickel MK, Nickel C, Kaplan P, et al.: Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004, 65:1515–1519.

    Article  PubMed  CAS  Google Scholar 

  40. Janowsky DS, Kraus JE, Barnhill J, et al.: Effects of topiramate on aggressive, self-injurious and disruptive/destructive behaviors in the intellectually disabled: a open-label retrospective study. J Clin Psychopharmacol 2003, 23:500–504.

    Article  PubMed  CAS  Google Scholar 

  41. Opp J, Tuxhorn I, May T, et al.: Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005, 14:476–484.

    Article  PubMed  Google Scholar 

  42. Dinkelacker V, Dietl T, Widman G, et al.: Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003, 4:537–547.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychology and Neuroscience, Baylor University, One Bear Place #97334, Waco, TX, 76798, USA

    Matthew S. Stanford

Authors
  1. Matthew S. Stanford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathaniel E. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah L. Lake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robyn M. Baldridge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew S. Stanford.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stanford, M.S., Anderson, N.E., Lake, S.L. et al. Pharmacologic treatment of impulsive aggression with antiepileptic drugs. Curr Treat Options Neurol 11, 383–390 (2009). https://doi.org/10.1007/s11940-009-0043-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-009-0043-3

Keywords

Search

Navigation